scholarly journals Detecting sleep apnoea syndrome in primary care with screening questionnaires and the Epworth sleepiness scale

2019 ◽  
Vol 211 (2) ◽  
pp. 65-70 ◽  
Author(s):  
Chamara V Senaratna ◽  
Jennifer L Perret ◽  
Adrian Lowe ◽  
Gayan Bowatte ◽  
Michael J Abramson ◽  
...  
Keyword(s):  
Primary Care ◽  
Epworth Sleepiness Scale ◽  
Sleep Apnoea ◽  
Sleep Apnoea Syndrome ◽  
Screening Questionnaires

Primary care diagnosis of sleep apnoea syndrome in the Girona Healthcare area

2017 ◽  
Author(s):  
Eric Rojas Calvera ◽  
Susana Mota Casals ◽  
Immaculada Castellà i Dagà ◽  
Anton Obrador Legares ◽  
Mercè Salvans Sagué ◽  
...  
Keyword(s):  
Primary Care ◽  
Sleep Apnoea ◽  
Sleep Apnoea Syndrome

Assessment of predictive ability of Epworth scoring in screening of patients with sleep apnoea

2011 ◽  
Vol 126 (4) ◽  
pp. 372-379 ◽  
Author(s):  
A Sil ◽  
G Barr
Keyword(s):  
Literature Review ◽  
Confidence Interval ◽  
Obstructive Sleep Apnoea ◽  
Epworth Sleepiness Scale ◽  
Predictive Ability ◽  
Sleep Apnoea ◽  
Obstructive Sleep Apnoea Syndrome ◽  
Sleep Apnoea Syndrome ◽  
Obstructive Sleep ◽  
Sleep Assessment

AbstractMethod:Numerous studies have considered the benefits, and the disadvantages, of the Epworth Sleepiness Scale. Following an extensive literature review, we found that the evidence was inconclusive as regards the diagnostic efficacy of Epworth scoring for obstructive sleep apnoea syndrome. We undertook a retrospective study of 343 patients who underwent a sleep assessment over a 10-year period at the Monklands Hospital.Analysis and results:A total of 238 patients did not have sleep apnoea whereas 105 patients did. The mean Epworth score in patients with obstructive sleep apnoea syndrome was 10.94 (95 per cent confidence interval 9.46–11.42), and in the non-apnoeic group it was 7.73 (95 per cent confidence interval 7.04–8.41). Logistic regression and receiver operating characteristic curves were used to assess the predictive ability of Epworth scoring. The scores only explained 7–10 per cent of the variation in the probability of occurrence of obstructive sleep apnoea syndrome. The odds ratio for Epworth scoring was 1.118, and only 69 per cent of cases were correctly classified by the Scale.Conclusions:The literature review suggested that the Epworth Sleepiness Scale is associated with a low effect size and/or low predictive value when correlated or regressed on the Apnoea–Hypopnoea Index or Respiratory Disturbance Index, thus limiting its value as a screening test. Our study concluded that the Epworth Scale is only marginally useful in predicting the occurrence of obstructive sleep apnoea syndrome. We believe that every patient with a direct or witnessed history of sleep apnoea with obstructive symptoms have some form of sleep assessment.

Obstructive sleep apnoea

2018 ◽  
Author(s):  
Sonya Craig ◽  
Sophie West
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Epworth Sleepiness Scale ◽  
Sleep Apnoea ◽  
The Other ◽  
Obstructive Sleep Apnoea Syndrome ◽  
Daytime Somnolence ◽  
Sleep Study ◽  
Sleep Apnoea Syndrome ◽  
Obstructive Sleep ◽  
Almost Continuous

Obstructive sleep apnoea (OSA) is caused by the repetitive closure of the pharynx during sleep, leading to sleep fragmentation and, often, daytime somnolence. Traditionally, it is defined as either the number of apnoeas (complete cessation of breathing for longer than 10 seconds) or hyponoeas (reduction in air flow by >50%) per hour in an overnight sleep study. However, it must be remembered that this definition is arbitrary, and OSA is better viewed as a spectrum with trivial snoring at one end and severe, almost continuous obstruction at the other. In addition to the sleep-study findings, if the patient is sleepy during the day, as defined by the Epworth Sleepiness Scale, then this condition is termed ‘obstructive sleep apnoea syndrome’. This distinction is important, as patients with this syndrome usually warrant treatment.

What Non-Alcoholic Fatty Liver Disease Has Got to Do with Obstructive Sleep Apnoea Syndrome and viceversa?

2014 ◽  
Vol 23 (3) ◽  
pp. 291-299 ◽  
Author(s):  
Giovanni Tarantino ◽  
Vincenzo Citro ◽  
Carmine Finelli
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Obstructive Sleep Apnoea ◽  
Fatty Liver Disease ◽  
Sleep Apnoea ◽  
Obstructive Sleep Apnoea Syndrome ◽  
Alcoholic Fatty Liver ◽  
Sleep Apnoea Syndrome ◽  
Obstructive Sleep ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnoea syndrome (OSAS) are common conditions, frequently encountered in patients with obesity and/or metabolic syndrome. NAFLD and OSAS are complex diseases that involve an interaction of several intertwined factors. Several lines of evidence lend credence to an immune system derangement in these patients, i.e. the low grade chronic inflammation status, reckoned to be the most important factor in causing and maintaining these two illnesses. Furthermore, it is emphasized the main role of spleen involvement, as a novel mechanism. In this review the contribution of the visceral adiposity in both NAFLD and OSAS is stressed as well as the role of intermittent hypoxia. Finally, a post on the prevention of systemic inflammation is made.Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; CCR2: chemokine (C-C motif) receptor 2; CRP: C-reactive protein; CPAP: continuous positive airway pressure; FFA: free fatty acid; IGF-I: insulin-like growth factor; IR: insulin resistance; IL-6: interleukin-6; IH: intermittent hypoxia; IKK-β: IκB kinase β; LPS: lipopolysaccharide; MCP-1: monocyte chemoattractant protein-1; NAFLD: non-alcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; NEFA: non-esterified fatty acid; NF-κB: nuclear factor-κB; OSAS: obstructive sleep apnoea syndrome; PAI-1: plasminogen activator inhibitor-1; ROS: reactive oxygen species; TNF-α: tumor necrosis factor-α; T2D: type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document